Chondroitin sulfate
- Generic Name
- Chondroitin sulfate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 24967-93-9
- Unique Ingredient Identifier
- -
- Background
Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. Chondroitin sulfate is composed of alternating 1,3-N-acetyl...
- Indication
Chondroitin sulfate, used with glucosamine, is indicated to alleviate pain and inflammation from primary osteoarthritis. This supplement is reported to improve joint function and slow disease progression. Osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues, mainly cartilage degradation, subchondral bone sclerosis ...
- Associated Conditions
- Back pain, Muscle Strain, Myalgia, Osteoarthritis (OA), Sprains, Articular inflammation
- Associated Therapies
- Eye lubrication, Joint supplementation therapy
Study on Structum® in Adult Patients with Osteoarthritis (TRUST)
- Conditions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 150
- Registration Number
- NCT06623773
- Locations
- 🇵🇱
Maciej Dołżyński, Bialystok, Poland
🇵🇱Piotr Ligocki, Bydgoszcz, Poland
🇵🇱Elżbieta Pietrus- Dunaszewska, Katowice, Poland
Phase I Clinical Study of Chondroitin Sulfate for Treatment of NEC
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 20
- Registration Number
- NCT06547424
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 604
- Registration Number
- NCT02079727
- Locations
- 🇨🇿
Interni a revmatologicka ordinace, Breclav, Czech Republic
🇧🇪Unité d'exploration du metabolism osseux, CHU, Polyclinique universitaires L-Brull, Liege, Belgium
🇵🇱Medica Pro Familia, Warszawa, Poland
Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Bioiberica
- Target Recruit Count
- 194
- Registration Number
- NCT01354145
- Locations
- 🇨🇦
Institut de Rhumatologie de Montréal, Montréal, Quebec, Canada
🇨🇦Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada
🇨🇦Groupe de Recherche en rhumatologie et maladies osseoues, Québec, Quebec, Canada
Chondroitin Sulfate for Crohn's Disease
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Registration Number
- NCT01245088
- Locations
- 🇺🇸
University Hospitals Case medical Center, Cleveland, Ohio, United States
Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 108
- Registration Number
- NCT01233739
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Catalunya, Spain
Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
- Conditions
- First Posted Date
- 2002-04-08
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 1588
- Registration Number
- NCT00032890
- Locations
- 🇺🇸
*Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸*Case Western Reserve University, Beachwood, Ohio, United States
🇺🇸Arthritis Consultation Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.